Evolus Inc diskutieren

Evolus obtained FDA approval for its product Jeuveau to treat patients with glabellar lines.

FDA approval was given to Jeuveau on the basis of the TRANSPARENCY program that treated over 2,100 patients with successful results.

Allergan has a competing product in the aesthetic market, known as Botox, which generated $3.58 billion in revenue in 2018 alone.

stratec stimmt der Buy-Einschätzung von klostergang zu

stratec stimmt am 20.05.2019 der Buy-Einschätzung von klostergang mit dem Kursziel 35$ zu.
Überschrift: Evolus obtained FDA approval for its product Jeuveau to treat patients with glabellar lines.